Results 31 to 40 of about 472,711 (314)

The influence of cerebrovascular disease in dementia with Lewy bodies and Parkinson's disease dementia

European Journal of Neurology, 2021
Lewy body dementia (LBD), including dementia with Lewy bodies (DLB) and Parkinson's disease dementia, is a common form of neurodegenerative dementia. The frequency and influence of comorbid cerebrovascular disease is not understood but has potentially ...
Zina Hijazi, N. Yassi, J. O'Brien, R. Watson   +3 more
semanticscholar   +1 more source

Cortical Lewy Body Dementia

Behavioural Neurology, 1990
In cortical Lewy body dementia the distribution of Lewy bodies in the nervous system follows that of Parkinson's disease, except for their greater profusion in the cerebral cortex. The cortical tangles and plaques of Alzheimer pathology are often present,
W. R. G. Gibb
doaj   +1 more source

Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. [PDF]

, 2019
The gold standard for a definitive diagnosis of Parkinson disease (PD) is the pathologic finding of aggregated α-synuclein into Lewy bodies and for Alzheimer disease (AD) aggregated amyloid into plaques and hyperphosphorylated tau into tangles.
Brundin, P, Cambi, F, Espay, AJ, Fasano, A, Fernandez, HH, Gan-Or, Z, Greenamyre, JT, Josephs, KA, Kauffman, MA, Lang, AE, Leverenz, JB, Litvan, I, Marsili, L, Mata, IF, Merola, A, Morgante, F, Perry, G, Sardi, SP, Savica, R, Schwarzschild, MA, Sherer, T, Simon, DK, Standaert, DG, Tanner, CM, Vizcarra, JA, Yamasaki, TR, Zabetian, CP   +26 more
core   +3 more sources

Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.

PLoS ONE, 2013
ObjectiveMost neurodegenerative diseases contain hyperphosphorylated Tau [p-Tau]. We examined for the first time epitopes at which Tau is hyperphosphorylated in Parkinson's disease, dementia with Lewy bodies and Alzheimer's disease, and also select Tau ...
Valeriy Duka, Jae-Hoon Lee, Joel Credle, Jonathan Wills, Adam Oaks, Ciaran Smolinsky, Ketul Shah, Deborah C Mash, Eliezer Masliah, Anita Sidhu   +9 more
doaj   +1 more source

Clinical characteristics with an impact on ADL functions of PD patients with cognitive impairment indicative of dementia. [PDF]

PLoS ONE, 2013
BackgroundDementia in Parkinson's disease (PD) is defined as cognitive decline severe enough to affect activities of daily living function (ADL). The aim of our exploratory study was to compare two groups of PD patients.
Inga Liepelt-Scarfone, Monika Fruhmann Berger, Deborah Prakash, Ilona Csoti, Susanne Gräber, Walter Maetzler, Daniela Berg   +6 more
doaj   +1 more source

Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36 [PDF]

, 2001
Kufor-Rakeb syndrome is an autosomal recessive nigro-striatal-pallidal-pyramidal neurodegeneration. The onset is in the teenage years with clinical features of Parkinson’s disease plus spasticity, supranuclear upgaze paresis, and dementia.
Al-Din, A., Bond, J., Crow, Y., Hampshire, D.J., Mubaidin, A., Roberts, E., Woods, C.G., Wriekat, A.L.   +7 more
core   +2 more sources

Ambroxol as a novel disease-modifying treatment for Parkinson’s disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial

BMC Neurology, 2019
BackgroundCurrently there are no disease-modifying treatments for Parkinson’s disease dementia (PDD), a condition linked to aggregation of the protein α-synuclein in subcortical and cortical brain areas.
C. Silveira, J. MacKinley, K. Coleman, Z. Li, E. Finger, E. Finger, R. Bartha, R. Bartha, S. Morrow, S. Morrow, J. Wells, J. Wells, M. Borrie, M. Borrie, R. Tirona, R. Tirona, C. Rupar, C. Rupar, Guangyong Zou, Guangyong Zou, R. Hegele, R. Hegele, R. Hegele, D. Mahuran, Penny A. MacDonald, M. Jenkins, M. Jenkins, M. Jog, M. Jog, S. Pasternak   +29 more
semanticscholar   +1 more source

Atypical parkinsonism: An Update. [PDF]

, 2013
Purpose of review: This update discusses novel aspects on genetics, diagnosis, and treatments of atypical parkinsonism published over the past 2 years. Recent findings: A genome-wide association study identified new genetic risk factors for progressive ...
Hoeglinger, GU, Stamelou, M
core   +1 more source

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia

Reactions weekly, 2017
Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer’s disease (AD) and Parkinson’s disease dementia (PDD).
N. Kandiah, M. Pai, V. Senanarong, I. Looi, E. Ampil, K. Park, Ananda Krishna Karanam, S. Christopher   +7 more
semanticscholar   +1 more source

Demência na doença de Parkinson Dementia in Parkinsn's disease

Brazilian Journal of Psychiatry, 2008
OBJETIVO: A presença de síndromes psiquiátricas, incluindo demência, associada a distúrbios motores tem sido cada vez mais reconhecida durante a última década, com destaque para o prejuízo cognitivo na doença de Parkinson idiopática.
Leonardo Caixeta, Renata Teles Vieira
doaj   +1 more source